Company intelligence / Profile preview
Trethera
Santa Monica, California, USAtrethera.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
TRE‑515, an orally delivered first-in-class inhibitor of deoxycytidine kinase, has received FDA Orphan Drug designation for two diseases. It has demonstrated tolerability and potential efficacy in early clinical development targeting both cancer and autoimmune disease by exploiting metabolic vulnerabilities unique to diseased cells. The company positions TRE‑515 as potentially safer with fewer side effects compared to traditional therapies.
- Therapeutic areas
- OncologyImmunologyRare Diseases
- Modalities
- Small molecules (notably oral small molecule inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with key academic groups including UCLA; pharmaceutical partnerships mentioned but not named specifically
Beyond the preview
Go deeper on Trethera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trethera.